GLS and Miyoshi myopathy: Elegant preclinical studies demonstrated that Eliglustat, an FDA-approved small GSL synthetic inhibitor used for the treatment of Gaucher disease type 1 in adults [136], was capable to reduce osteoclast-driven bone loss in MGUS and MM models, acting as autophagy inhibitor which prevents TRAF3 degradation through a GLS-dependent mechanism [137].